Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic and proteomic approaches to renal cell carcinoma.
Zacchia M, Vilasi A, Capasso A, Morelli F, De Vita F, Capasso G. Zacchia M, et al. Among authors: morelli f. J Nephrol. 2011 Mar-Apr;24(2):155-64. doi: 10.5301/jn.2010.90. J Nephrol. 2011. PMID: 20437403 Review.
Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma.
Lucarelli G, Rutigliano M, Ferro M, Giglio A, Intini A, Triggiano F, Palazzo S, Gigante M, Castellano G, Ranieri E, Buonerba C, Terracciano D, Sanguedolce F, Napoli A, Maiorano E, Morelli F, Ditonno P, Battaglia M. Lucarelli G, et al. Among authors: morelli f. Urol Oncol. 2017 Jul;35(7):461.e15-461.e27. doi: 10.1016/j.urolonc.2017.02.011. Epub 2017 Mar 28. Urol Oncol. 2017. PMID: 28359744
Toward a genome-based treatment landscape for renal cell carcinoma.
Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, Bracarda S. Massari F, et al. Among authors: morelli f. Crit Rev Oncol Hematol. 2019 Oct;142:141-152. doi: 10.1016/j.critrevonc.2019.07.020. Epub 2019 Aug 2. Crit Rev Oncol Hematol. 2019. PMID: 31401421 Review.
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Porta C, Bamias A, Zakopoulou R, Myint ZW, Cavasin N, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, DE Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Mollica V, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Zabalza IO, Rizzo A, Bisonni R, Pierantoni F, Sorgentoni G, Monteiro FS, Battelli N, Buti S, Santoni M. Porta C, et al. Among authors: morelli f. Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7. Minerva Urol Nephrol. 2023. PMID: 37530662 Free article.
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: morelli f. Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216384 Free article.
305 results